Drug hypersensitivity syndrome: drug rash with eosinophila and systemic symptoms (DRESS)

References

• Salzstein S L, Ackerman L V. Lymphadenopathy induced by anti-convulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 1959; 12: 164–82
   Google Scholar
• Schreiber M M, McGregor J G. Pseudolymphoma syndrome. A sensitivity to anticonvulsant drugs. Arch Dermatol 1968; 97: 297–300
   PubMed Web of Science ®Google Scholar
• Wilson J T, Hojer B, Tomson G, et al. High incidence of a concentration dependent skin reaction in children treated with phenytoin. BMJ 1978; 1: 1583–6
   PubMed Web of Science ®Google Scholar
• Engel J N, Mellul V G, Goodman D. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. Am J Med 1986; 81: 928–30
   PubMed Web of Science ®Google Scholar
• Michael J R, Mitch W E. Reversible renal failure and myositis caused by phenytoin hypersensitivity. JAMA 1976; 236: 2773–5
   Google Scholar
• Stanley J, Fallon-Pellicci V. Phenytoin hypersensitivity reactions. Arch Dermatol 1978; 114: 1350–3
   Google Scholar
• Chaiken B H, Goldberg B I, Segal J P. Dilantin hypersensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242: 897–8
   PubMed Web of Science ®Google Scholar
• Conger L A, Grabski W J. Dilantin hypersensitivity reaction. Cutis 1996; 57: 223–6
   Google Scholar
• Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology 1979; 29: 1480–5
   PubMed Web of Science ®Google Scholar
• Harris D WS, Ostlere L, Buckley C, et al. Phenytoin-induced pseudolymphoma. A report of a case and review of the literature. Br J Dermatol 1992; 127: 403–6
   PubMed Web of Science ®Google Scholar
• D'Incan M, Souteyrand P, Bignon Y J, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch Dermatol 1992; 128: 1371–4
   PubMed Web of Science ®Google Scholar
• Rosenthal C J, Noguera C A, Cappola A, Kapelner S N. Pseudo lymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte deregulation. Cancer 1982; 49: 2305–14
   PubMed Web of Science ®Google Scholar
• Shear N H, Spielberg S P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826–32
   PubMed Web of Science ®Google Scholar
• Parneix-Spake A, Bastuji-Garin S, Lobut J B, et al. Minocycline as possible cause of severe and protracted hyper-sensivity drug reaction. Arch Dermatol 1995; 131: 490–1
   PubMedGoogle Scholar
• Brown M D, Ellis C N, Billings J, et al. Rapid occurrence of nodular cutaneous T-lymphocyte infiltrates with ciclos-porine therapy. Arch Dermatol 1988; 124: 1097–100
   PubMed Web of Science ®Google Scholar
• Raymond J Z, Goldman H M. An unusual cutaneous reaction secondary to allopurinol. Cutis 1988; 41: 323–6
   Google Scholar
• Bagot M, Wechsler J, Perrussel M, et al. Pseudolym-phome induit par la ciclosporine. Ann Dermatol Venereol 1989; 116: 894–6
   Google Scholar
• Lavrijen A PM, Van Dijke C, Vermeer B J. Diltiazem-associated exfoliative dermatitis in a patient with psoriasis. Acta Derm Venereol (Stockh) 1986; 66: 536–8
   Google Scholar
• Furness P N, Goodfield M J, Maclennan K A, et al. Severe cutaneous reactions to captopril and enalapril: histological study and comparison with early mycosis fungoides. J Clin Pathol 1986; 39: 902–7
   Google Scholar
• Mills R M. Severe hypersensitivity reactions associated with allopurinol. JAMA 1971; 216: 799–802
   Google Scholar
• Sotolongo R P, Necfe L I, Rudzki C, Ishak K G. Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology 1978; 75: 95–9
   PubMed Web of Science ®Google Scholar
• Sawaishi Y, Komatsu K, Takeda O, et al. A case of tubulo-interstitial nephritis with exfoliative dermatitis and hepatitis due to phenobarbital hypersensitivity. Eur J Pediatr 1992; 151: 69–72
   PubMedGoogle Scholar
• Stern R, Khalsa J H. Cutaneous adverse reaction associated with calcium channel blockers. Arch Intern Med 1989; 149: 829–32
   PubMed Web of Science ®Google Scholar
• Tomecki K J, Catalano C J. Dapsone hypersensitivity. The sulfone syndrome revisited. Arch Dermatol 1981; 117: 38–9
   Google Scholar
• Davies M G, Kersey P JW. Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ 1989; 298: 1523–4
   PubMedGoogle Scholar
• Maberly D J, Greenhalgh R M. Jaundice and exfoliative dermatitis due to phenylbutazone. Br J Dermatol 1970; 82: 618–19
   Google Scholar
• Henderson C A, Shamy H K. Atenolol-induced pseudo-lymphoma. Clin Exp Dermatol 1990; 15: 119–20
   Google Scholar
• Diffee J J, Hayes J M, Montesi S C, et al. Chlorpropamide-induced pulmonary infiltration and eosinophilia with multisystem toxicity. J Tenn Med Assoc 1986; 79: 82–4
   Google Scholar
• Prussick R, Shear N H. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996; 35: 346–9
   PubMed Web of Science ®Google Scholar
• Compton M R, Crosby D L. Rhabdomyolysis associated with azathioprine hypersensitivity syndrome. Arch Dermatol 1996; 132: 1254–5
   Google Scholar
• Knowles S R, Shapiro L, Shear N H. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996; 132: 934–9
   PubMed Web of Science ®Google Scholar
• Cox N H, Johnston S RD, Marks J, Bates D. Extensive car-bamazepine eruption with eosinophilia and pulmonary infiltrate. Postgrad Med J 1988; 64: 249–54
   Google Scholar
• De Vriese A SP, Philippe J, Van Renterghem D M, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine 1995; 74: 144–51
   PubMed Web of Science ®Google Scholar
• Goodfield M J, Millard L G. Severe cutaneous reactions to captopril. BMJ 1985; 290: 1111
   Google Scholar
• Bonnetblanc J M. Drug hypersensitivity syndrome. Dermatology 1993; 187: 84–5
   Google Scholar
• Callot V, Roujeau J C, Bagot M, et al. Drug induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996; 132: 1315–21
   PubMedGoogle Scholar
• Bocquet H, Bagot M, Roujeau J C. Drug-induced pseudo-lymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250–7
   PubMed Web of Science ®Google Scholar
• Roujeau J C, Stern R S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85
   PubMed Web of Science ®Google Scholar
• Silverman A K, Fairley J, Wong R C. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988; 18: 721–41
   PubMed Web of Science ®Google Scholar
• Vittorio C C, Muglia J J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285–90
   PubMed Web of Science ®Google Scholar
• Kleir R S, Breneman D L, Boiho S. Generalized pustula-tion as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991; 127: 1361–4
   Google Scholar
• Kardaun S H, Scheffer E, Vermeer B J. Drug induced pseu-dolymphomatous skin reactions. Br J Dermatol 1988; 118: 545–52
   Google Scholar
• Parker W A, Shearer C A. Phenytoin hepatotoxicity: a case report and review. Neurology 1979; 29: 175–8
   PubMed Web of Science ®Google Scholar
• Ting S, Dunsky E H. Diphenylhydantoin-induced hepatitis. Ann Allergy 1982; 48: 331–2
   PubMedGoogle Scholar
• Handfield-Jones S E, Jankins R E, Whittaker S J, et al. The anticonvulsant hypersensitivity svndrome. Br J Dermatol 1993; 129: 175–7
   Google Scholar
• Tennis P, Stern R S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine or sodium valproate: a record linkage study. Neurology 1997; 49: 542–6
   PubMed Web of Science ®Google Scholar
• Jones D, Chiap V, Resor S, et al. Phenytoin-like hypersensitivity associated with lamotrigine. J Am Acad Dermatol 1997; 36: 1016–18
   Google Scholar
• Grossman S J, Jollow D J. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther 1988; 244: 118–25
   PubMed Web of Science ®Google Scholar
• Shear N H, Spielberg S P, Grant D M, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179–84
   PubMed Web of Science ®Google Scholar
• Rieder M J, Shear N S, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13–17
   PubMed Web of Science ®Google Scholar
• Rieder M J, Vetrecht J, Shear N S, et al. Diagnosis of suifonamide hypersensitivity reactions by in-vitro ‘rechallenge’ with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286–9
   PubMed Web of Science ®Google Scholar
• Roujeau J C, Kelly J P, Naldi L, et al. Medication use and the risk of Stevens-Johnson or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7
   PubMed Web of Science ®Google Scholar
• Shapiro L E, Knowles S R, Shear N H. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224–30
   PubMed Web of Science ®Google Scholar
• Gleichmann H. Studies on the mechanison of drug sensitization: T-cell dependent popliteal lymph reaction to diphenylhydantoin. Clin Immunol Immunopathol 1981; 18: 203–24
   PubMedGoogle Scholar
• Dosch H M, Jason J, Gelfand E W. Transient antibody deficiency and abnormal T-cells induced by phenytoin. N Engl J Med 1982; 306: 406–9
   PubMed Web of Science ®Google Scholar
• Bluming A, Homer S, Khiroya R. Selective diphenylhydantoin induced suppression of lymphocyte reactivity in vitro. J Lab Clin Med 1976; 88: 417–22
   Google Scholar
• Descamps V, Bouscarat F, Laglenne S, et al. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997; 137: 605–8
   PubMedGoogle Scholar
• Bocquet H, Bourgault-Villada I, Delfau-Larue M H, et al. Syndrome d'hypersensibilité à la dapsone. Clone T circulant transitoire. Ann Dermatol Venereol 1995; 122: 514–16
   Google Scholar
• Shapiro L E, Shear N H. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 1996; 15: 217–27
   Google Scholar
• Spielberg S P, Gordon G B, Blake D A, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722–7
   PubMed Web of Science ®Google Scholar
• Spielberg S P. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc 1984; 43: 2308–13
   PubMedGoogle Scholar
• Gennis M A, Vemori R, Burns C A, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631–4
   PubMed Web of Science ®Google Scholar
• Shear N H, Spielberg S P. In vitro evaluation of a metabolites of sulfadiazide. Can J Physiol Pharmacol 1985; 63: 1370–2
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Carríre V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255–8
   PubMedGoogle Scholar
• Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995; 131: 544–51
   PubMed Web of Science ®Google Scholar
• Lee B L, Wong D, Bewowitz N L, Sullam P M. Altered pattern of drug metabolism in patients with acquired immuno-deficiency syndrome. Clin Pharmacol Ther 1993; 53: 529–35
   PubMed Web of Science ®Google Scholar
• Buhl R, Jaffe H A, Holroyd K J, et al. Systemic glutathione deficiency in symptom-free HIV seropositive individuals. Lancet 1989; 2: 1294–8
   PubMed Web of Science ®Google Scholar
• Chopra S, Levell N J, Cowley G, Gilkes J J. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol 1996; 134: 1109–12
   PubMedGoogle Scholar